LOGIN  |  REGISTER
Terns Pharmaceuticals
Viking Therapeutics

Certara to Participate in Upcoming Investor Conferences

August 31, 2021 | Last Trade: US$12.99 0.38 3.01

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference
    Date and Time: Tuesday, September 14 at 9:30 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer
  • Baird 2021 Global Healthcare Conference
    Date and Time: Wednesday, September 15 at 4:55 p.m. ET
    Speaker: Andrew Schemick, chief financial officer
  • Bank of America Securities 2021 Tech Solutions for Drug Discovery Conference
    Date and Time: Monday, September 20 at 8:00 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page